Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction

B. Habelt, D. Afanasenkau, C. Schwarz, K. Domanegg, M. Kuchar, C. Werner, IR. Minev, R. Spanagel, MW. Meinhardt, N. Bernhardt

. 2024 ; 14 (1) : 486. [pub] 20241205

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003076

Grantová podpora
521379614 Deutsche Forschungsgemeinschaft (German Research Foundation)
402170461 Deutsche Forschungsgemeinschaft (German Research Foundation)
ME 5279/3-1 Deutsche Forschungsgemeinschaft (German Research Foundation)
402170461 Deutsche Forschungsgemeinschaft (German Research Foundation)
91690 Volkswagen Foundation (VolkswagenStiftung)
804005 EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
01EW1908 Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
01ZX1909A Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
01EW1908 Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)

Patients with alcohol use disorder (AUD) who seek treatment show highly variable outcomes. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse. We reasoned here that prefrontal dysfunction, which underlies vulnerability to relapse, is evidenced by altered neuroelectric signatures and should be restored by pharmacological interventions that specifically target prefrontal dysfunction. To test this, we applied our recently developed biocompatible neuroprosthesis to measure prefrontal neural function in a well-established rat model of alcohol addiction and relapse. We monitored neural oscillations and event-related potentials in awake alcohol-dependent rats during abstinence and following treatment with psilocybin or LY379268, agonists of the serotonin 2A receptor (5-HT2AR), and the metabotropic glutamate receptor 2 (mGluR2), that are known to reduce prefrontal dysfunction and relapse. Electrophysiological impairments in alcohol-dependent rats are reduced amplitudes of P1N1 and N1P2 components and attenuated event-related oscillatory activity. Psilocybin and LY379268 were able to restore these impairments. Furthermore, alcohol-dependent animals displayed a dominance in higher beta frequencies indicative of a state of hyperarousal that is prone to relapse, which particularly psilocybin was able to counteract. In summary, we provide prefrontal markers indicative of relapse and treatment response, especially for psychedelic drugs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003076
003      
CZ-PrNML
005      
20250206104030.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41398-024-03189-z $2 doi
035    __
$a (PubMed)39639028
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Habelt, Bettina $u Department of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany $u Leibniz Institute of Polymer Research Dresden, Dresden, Germany
245    10
$a Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction / $c B. Habelt, D. Afanasenkau, C. Schwarz, K. Domanegg, M. Kuchar, C. Werner, IR. Minev, R. Spanagel, MW. Meinhardt, N. Bernhardt
520    9_
$a Patients with alcohol use disorder (AUD) who seek treatment show highly variable outcomes. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse. We reasoned here that prefrontal dysfunction, which underlies vulnerability to relapse, is evidenced by altered neuroelectric signatures and should be restored by pharmacological interventions that specifically target prefrontal dysfunction. To test this, we applied our recently developed biocompatible neuroprosthesis to measure prefrontal neural function in a well-established rat model of alcohol addiction and relapse. We monitored neural oscillations and event-related potentials in awake alcohol-dependent rats during abstinence and following treatment with psilocybin or LY379268, agonists of the serotonin 2A receptor (5-HT2AR), and the metabotropic glutamate receptor 2 (mGluR2), that are known to reduce prefrontal dysfunction and relapse. Electrophysiological impairments in alcohol-dependent rats are reduced amplitudes of P1N1 and N1P2 components and attenuated event-related oscillatory activity. Psilocybin and LY379268 were able to restore these impairments. Furthermore, alcohol-dependent animals displayed a dominance in higher beta frequencies indicative of a state of hyperarousal that is prone to relapse, which particularly psilocybin was able to counteract. In summary, we provide prefrontal markers indicative of relapse and treatment response, especially for psychedelic drugs.
650    _2
$a zvířata $7 D000818
650    12
$a prefrontální mozková kůra $x účinky léků $x patofyziologie $x metabolismus $7 D017397
650    12
$a alkoholismus $x farmakoterapie $x patofyziologie $7 D000437
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a mužské pohlaví $7 D008297
650    12
$a bicyklické sloučeniny heterocyklické $x farmakologie $7 D019086
650    12
$a psilocybin $x farmakologie $7 D011562
650    _2
$a biologické markery $7 D015415
650    _2
$a evokované potenciály $x účinky léků $7 D005071
650    _2
$a aminokyseliny $7 D000596
650    _2
$a receptory metabotropního glutamátu $7 D018094
655    _2
$a časopisecké články $7 D016428
700    1_
$a Afanasenkau, Dzmitry $u Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Technische Universität Dresden, Dresden, Germany
700    1_
$a Schwarz, Cindy $u Department of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Domanegg, Kevin $u Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
700    1_
$a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic $u Psychedelic Research Center, National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a Werner, Carsten $u Leibniz Institute of Polymer Research Dresden, Dresden, Germany
700    1_
$a Minev, Ivan R $u Leibniz Institute of Polymer Research Dresden, Dresden, Germany $u Else Kröner Fresenius Center for Digital Health, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Spanagel, Rainer $u Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany $u German Center for Mental Health (DZPG), partner site Mannheim/Heidelberg/Ulm, Mannheim, Germany $1 https://orcid.org/0000000321514521
700    1_
$a Meinhardt, Marcus W $u Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. marcus.meinhardt@zi-mannheim.de $u Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. marcus.meinhardt@zi-mannheim.de $1 https://orcid.org/0000000251030731
700    1_
$a Bernhardt, Nadine $u Department of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. nadine.bernhardt@uniklinikum-dresden.de $1 https://orcid.org/0000000231888431
773    0_
$w MED00177206 $t Translational psychiatry $x 2158-3188 $g Roč. 14, č. 1 (2024), s. 486
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39639028 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104026 $b ABA008
999    __
$a ok $b bmc $g 2263067 $s 1239083
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 486 $e 20241205 $i 2158-3188 $m Translational psychiatry $n Transl Psychiatry $x MED00177206
GRA    __
$a 521379614 $p Deutsche Forschungsgemeinschaft (German Research Foundation)
GRA    __
$a 402170461 $p Deutsche Forschungsgemeinschaft (German Research Foundation)
GRA    __
$a ME 5279/3-1 $p Deutsche Forschungsgemeinschaft (German Research Foundation)
GRA    __
$a 402170461 $p Deutsche Forschungsgemeinschaft (German Research Foundation)
GRA    __
$a 91690 $p Volkswagen Foundation (VolkswagenStiftung)
GRA    __
$a 804005 $p EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
GRA    __
$a 01EW1908 $p Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
GRA    __
$a 01ZX1909A $p Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
GRA    __
$a 01EW1908 $p Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...